Crinetics Pharmaceuticals (CRNX) Total Liabilities (2017 - 2026)

Crinetics Pharmaceuticals' Total Liabilities history runs 10 years deep, the most recent figure standing at $120.7 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 12.44% year-over-year to $120.7 million; the TTM figure through Mar 2026 stood at $120.7 million (up 12.44% YoY), while the FY2025 annual figure was $134.2 million, up 22.21% from the prior year.
• Total Liabilities for Q1 2026 stood at $120.7 million, down from $134.2 million in the prior quarter.
• The five-year high for Total Liabilities was $134.2 million in Q4 2025, with the low at $30.2 million in Q1 2022.
• The 5-year median for Total Liabilities is $103.2 million (2024), against an average of $83.8 million.
• The sharpest annual moves came in 2024 and 2025: Total Liabilities jumped 206.48% in 2024, then climbed 3.98% in 2025.
• Crinetics Pharmaceuticals' Total Liabilities stood at $35.8 million in 2022, then surged by 168.49% to $96.2 million in 2023, then climbed by 14.07% to $109.8 million in 2024, then gained by 22.21% to $134.2 million in 2025, then slipped by 10.06% to $120.7 million in 2026.
• Business Quant data shows CRNX's Total Liabilities at $120.7 million in Q1 2026, $134.2 million in Q4 2025, and $123.9 million in Q3 2025.